Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

3S Bio (01530.HK) reported first-half 2026 results from its interim update released in Shanghai on Aug. 21, 2026. Revenue rose to RMB 4.53 billion, up 3.9% year-over-year, while net profit attributable to equity holders reached RMB 1.15 billion. Adjusted operating net profit attributable to the parent’s shareholders was RMB 1.44 billion, up 26.5%. R&D expenses totaled RMB 680 million (+24.9%), and cash resources stood at RMB 19.4 billion. The company secured marketing approvals in 23 countries for core products and saw overseas sales increase 43%. In licensing, Pfizer accelerated global trials for PF-08634404 (SSGJ-707), tied to an over US$6 billion potential deal.